DLL3 and small cell lung carcinoma: A phase 1 first-in-human study with DLL3-targeted chimeric antigen receptor T cells (LB2102) and a phase 1 with autologous CAR T cells against the GD2 antigen in patients with advanced lung cancer, NSCLC and SCLC, are being planned (NCT05680922 and NCT05620342).